Related Experiment Videos
[Topoisomerase inhibitors developing in Japan]
1Fourth Dept. of Internal Medicine, Teikyo University.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1993
Summary
Investigational topoisomerase inhibitors irinotecan hydrochloride (CPT-11) and topotecan show efficacy in various cancers. Other agents like sobuzoxane, NC-190, and IST-622 are also being studied for their anticancer properties.
Area of Science:
- Oncology
- Pharmacology
Background:
- Topoisomerase inhibitors are a significant class of anticancer agents.
- Irinotecan hydrochloride (CPT-11), topotecan, sobuzoxane, NC-190, and IST-622 are investigational drugs in Japan targeting topoisomerases.
Purpose of the Study:
- To review the status and preliminary findings of novel topoisomerase inhibitors under investigation in Japan.
- To highlight their mechanisms of action, therapeutic potential, and toxicities.
Main Methods:
- Review of clinical trial data and preclinical studies for CPT-11, topotecan, sobuzoxane, NC-190, and IST-622.
- Summary of efficacy in various cancer types and dose-limiting toxicities.
Main Results:
- CPT-11 and topotecan (topoisomerase I inhibitors) demonstrate efficacy in lung, cervical, ovarian, stomach, colon cancers, and lymphoma, with leukopenia and diarrhea as dose-limiting toxicities.
- Sobuzoxane, NC-190, and IST-622 (topoisomerase II inhibitors) show activity in non-Hodgkin's lymphoma, adult T-cell leukemia/lymphoma, and various murine tumors, with myelosuppression as a common toxicity.
Conclusions:
- These novel topoisomerase inhibitors represent promising therapeutic options for various malignancies.
- Further clinical evaluation is warranted to establish their role in cancer treatment.